STAGE IIIB LUNG CANCER AJCC V8

This phase 3 study looks at the best way to treat advanced non-squamous non-small cell lung cancer. It compares starting with immunotherapy alone (pembrolizumab) versus starting with immunotherapy plus chemotherapy (pemetrexed and carboplatin). The goal is to see which approach h…

This early-phase study tests the safety and best dose of adding minnelide to the standard drug osimertinib for people with advanced non-small cell lung cancer that has an EGFR mutation. The goal is to see if the combination can better control tumor growth. About 8 adults with adv…

This study looks at whether adding radiation therapy to standard immunotherapy (with or without chemotherapy) can help people with advanced non-small cell lung cancer that is PD-L1 negative. About 427 participants with stage IIIB to IV lung cancer will be randomly assigned to rec…

This early-phase study tests a drug called NBTXR3, which makes cancer cells more sensitive to radiation, combined with a second round of radiation for people whose non-small cell lung cancer has returned and cannot be removed by surgery. The main goals are to find the safest dose…

This study tests whether adding a drug called AZD6738 to the immunotherapy durvalumab can help keep lung cancer from returning in patients who have already had chemotherapy and surgery. About 630 adults with stage II to IIIB non-small cell lung cancer will take part. The goal is …

This early-phase study is for people with a specific kind of advanced lung cancer (ALK-positive non-small cell lung cancer) that has gotten worse despite prior ALK-targeted therapy. The trial combines two drugs: brigatinib (which blocks cancer growth signals) and bevacizumab (whi…

This study compares two treatments for lung lesions in people with non-small cell lung cancer, sarcoma, or colorectal cancer that has spread. One treatment uses microwave energy to heat and kill tumor cells, while the other is a small surgery to remove the tumor. Researchers want…

This study tests whether adding tocilizumab to two standard immunotherapy drugs (ipilimumab and nivolumab) can reduce severe side effects while still fighting cancer. About 35 adults with advanced melanoma, non-small cell lung cancer, or bladder cancer will receive the combinatio…

This study tests a new drug combination for people with advanced EGFR-mutant non-small cell lung cancer. The two drugs, LY3295668 and osimertinib, work by blocking enzymes that help cancer cells grow. The goal is to find the best dose and see if the combination can control the di…

This study tests whether adding the immunotherapy drug durvalumab to standard chemoradiation (and continuing it afterward) helps people with stage 3 lung cancer that can't be surgically removed live longer or keep the cancer from coming back. About 660 adults with newly diagnosed…

This early-phase study tests a new treatment for people with advanced non-small cell lung cancer that no longer responds to standard immunotherapy. The treatment uses specially engineered immune cells from umbilical cord blood, designed to better recognize and attack cancer cells…

This study tests a combination of two drugs, trametinib and pembrolizumab, in people with advanced non-small cell lung cancer that has returned or spread. The goal is to see how well this treatment works based on specific genetic markers in each patient's tumor. About 37 particip…

This study looks at whether adding surgery or radiation to the targeted therapy osimertinib can help people with advanced EGFR-mutant non-small cell lung cancer live longer without the disease getting worse. About 173 participants with stage IIIB or IV lung cancer will be randoml…

This study tests a combination of the CIMAvax vaccine (which targets a protein that helps tumors grow) and nivolumab (an immunotherapy that boosts the immune system) in people with advanced non-small cell lung cancer or squamous head and neck cancer. The goal is to find the best …

This early-phase trial tests whether combining two immunotherapy drugs (ipilimumab and nivolumab) with radiation therapy is safe and effective for people with stage II or III non-small cell lung cancer that cannot be removed by surgery. The study includes 21 participants and aims…

This study tests two drugs together—niraparib and dostarlimab—for people with small cell lung cancer or other high-grade neuroendocrine cancers that have already been treated. The goal is to see if the combination can shrink tumors or slow the disease. About 48 adults will take p…

This study tests a combination of three drugs (niraparib, temozolomide, and atezolizumab) in people with advanced solid tumors or extensive-stage small cell lung cancer. The goal is to find the safest dose and see if the combination helps keep the cancer from growing longer than …

This study tests whether a lung cancer drug called atezolizumab can be safely given at home by a nurse, with doctor visits done by video call. It involves 5 adults with non-small cell lung cancer. The goal is to see if this home-based approach is practical and safe.

This study tests a new drug, pevonedistat, combined with standard chemotherapy (carboplatin and paclitaxel) in people with advanced non-small cell lung cancer that has already been treated with immunotherapy. The goal is to see if this combination can shrink tumors or stop them f…

This early-stage trial looks at whether giving one very precise, high-dose radiation treatment after lung cancer surgery is safe and causes fewer side effects than the usual weeks of daily radiation. About 50 adults with non-small cell lung cancer who had surgery but still have s…

This study tests an online program designed to improve social well-being and emotional support for women with non-small cell lung cancer. About 70 women currently receiving treatment will use mindfulness and compassion techniques to help manage distress. The goal is to see if the…

This study tests a telehealth self-management program for people who have finished treatment for early-stage lung or colorectal cancer. The program coaches survivors on follow-up care, communication with doctors, and managing their health. Researchers want to see if it improves c…

This study looks at whether a drug called anamorelin can help improve appetite and stop weight loss in people with advanced non-small cell lung cancer who have lost their appetite. About 25 participants will take either the drug or a placebo and share their experiences through in…

This study tests a nurse-led program designed to help people with advanced lung or gynecologic cancer cope with fears about their future. The program teaches practical ways to manage worry and unhelpful thoughts. The study includes 42 participants and focuses on whether the progr…

This study screens people with stage IB-IIIA non-small cell lung cancer that has been or will be removed by surgery. By analyzing the genes in their tumor tissue, doctors hope to identify which patients might benefit from specific targeted therapies. The goal is to better persona…

This study follows over 1,300 people with breast, lung, or ovarian cancer who are starting a type of chemotherapy called taxane. The goal is to find out which patients are more likely to develop nerve damage (peripheral neuropathy), which can cause tingling or numbness in the han…